New Delhi,

新德里，

Zydus Lifesciences

瑞迪博士实验室

and

和

Torrent Pharmaceuticals

Torrent制药公司

have inked a licensing and supply agreement to co-market

签署了许可和供应协议以共同营销

diabetes treatment

糖尿病治疗

medication

药物

Semaglutide Injection

司美格鲁肽注射液

in the Indian market.

在印度市场。

Under the terms of the agreement, Zydus will manufacture and supply the product, while Torrent Pharma has received semi-exclusive rights to co-market the product in India under its own brand name Sembolic, leveraging its strong presence in chronic therapies and extensive field force across the country, the Gujarat-based drugmaker said in a statement..

根据协议条款，Zydus将负责生产并供应该产品，而Torrent Pharma已获得在印度以自有品牌Sembolic共同营销该产品的半独家权利。这家总部位于古吉拉特邦的制药商在一份声明中表示，Torrent Pharma将利用其在慢性病治疗领域的强大影响力和遍布全国的广泛销售团队。

As part of the agreement, Torrent Pharma will pay an upfront licensing fee to Zydus, it added.

作为协议的一部分，Torrent Pharma将向Zydus支付预付许可费，声明补充道。

Zydus has developed an innovative formulation of Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a reusable pen device.

Zydus 开发了一种创新的司美鲁肽注射液（15 毫克/3 毫升）配方，该配方以预填充卡匣形式提供，并通过可重复使用的笔式装置给药。

Semaglutide is indicated for the treatment of adults with

Semaglutide 适用于治疗成人

insufficiently controlled type 2 diabetes

控制不佳的2型糖尿病

mellitus. It is also indicated for

糖尿病。它也适用于

chronic weight management

慢性体重管理

in adults.

在成人中。

Add

添加

as a Reliable and Trusted News Source

作为可靠和值得信赖的新闻来源

Add Now!

立即添加！

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)